Bal Pharma Ltd.

GlaxoSmithKline (GSK) has agreed to purchase the remaining 36.5% share in GlaxoSmithKline Consumer Healthcare from Novartis for $13bn. GSK has appointed Citigroup, JP Morgan Cazenove and Greenhill & Co as financial advisors for the transaction. The acquisition will improve GSK’s capital allocation plan and remove uncertainty regarding the business. Based in the UK, the acquirer company is a pharmaceutical company, while the target company is a Swiss provider of nutritional and over the counter (OTC) medical products. Indian pharmaceutical company Bal Pharma has purchased 100% interest in Golden Drugs Pvt. Ltd (Golden Drugs). The target company is a producer of pharma medicines, paracetamol, tablets and capsules. It will operate as a subsidiary of Bal Pharma upon completion of the acquisition. Private equity firm NovaQuest Capital Management has acquired specialist pharmaceutical company Cutispharma. Cutispharma has received financing from Goldman Sachs Specialist Lending Group as part of the transaction. Both companies involved in the transaction are based in the US. The acquisition will support CutisPharma’s growth plans. CutisPharma has appointed TAP Advisors as financial advisor for the transaction. Japanese R&D-driven pharmaceutical company Takeda Pharmaceutical plans to acquire Shire, a biotechnology company based in Ireland. Takeda will approach Shire regarding a possible offer by April. China-based pharmaceutical company Hunan Fangsheng Pharmaceutical has agreed to invest $3m in LipoMedics. The target company is involved in the development of personalised paclitaxel therapy. The investment will increase Hunan Fangsheng Pharmaceutical’s share in Lipomedics to 35.95%. India-based import and export company Shree Surgovind Tradelink has agreed to purchase pharmaceutical company RR Lifecare. RR Lifecare will become a subsidiary of Shree Surgovind Tradelink, upon completion of the acquisition.